1 has been suggested to play key roles in atherogenesis. In particular, modulation of endothelial functions elicited by Ox-LDL and its lipid constituents has been implicated in the initiation of this complex disease process (1, 2) . LOX-1 (lectin-like Ox-LDL receptor-1) is a type II membrane protein with a short N-terminal cytoplasmic domain and a long C-terminal extracellular domain whose structure belongs to the C-type lectin family (3) . Interestingly, LOX-1 does not share any homology with other receptors for Ox-LDL, including class A and B scavenger receptors. Functional analysis revealed that LOX-1 supports the binding, internalization, and proteolytic degradation of Ox-LDL, but not significant amounts of acetylated LDL (4) . LOX-1 can also bind aged red blood cells as well as apoptotic cells (5) . Expression of LOX-1 can be up-regulated by tumor necrosis factor-␣ (TNF-␣), phorbol 12-myristate 13-acetate, and fluid shear stress in cultured vascular endothelial cells, suggesting that LOX-1 expression appears to be dynamically regulated by inflammatory and fluid mechanical stimuli (6, 7) . LOX-1 expression is not restricted to vascular endothelial cells, but has been detected in human and murine macrophages in vitro (8, 9) . Furthermore, our recent study has revealed that LOX-1 is expressed by endothelial cells, macrophages, and smooth muscle cells in human carotid atherosclerotic lesions in vivo (10) . These results thus indicate that LOX-1 may play an important role in the pathogenesis of atherosclerosis.
Bovine LOX-1 cDNA contains an open reading frame of 810 base pairs that encodes a protein of 270 amino acid residues with a calculated molecular mass of 30,872 Da. The expressed protein in CHO cells and BAECs has a molecular mass of 48 kDa (3) . This difference may possibly result from the addition of carbohydrates at four potential N-linked glycosylation sites located in the C-terminal domain; however, this remains to be clarified. In this study, we provide evidence, for the first time, that LOX-1 is synthesized as a 40-kDa precursor form (pre-LOX-1), which is rapidly converted into the mature form with N-linked oligosaccharide chains. In addition, we show that N-linked glycosylation is necessary for the efficient cell-surface expression of LOX-1 in BAECs and that the deglycosylated form of LOX-1 has a lower affinity for the binding of Ox-LDL.
EXPERIMENTAL PROCEDURES
Cell Culture-BAECs were isolated by scraping the inner surface of bovine aortas with a glass coverslip and were cultured in Dulbecco's modified Eagle's medium (DMEM; Nissui) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; Sanko Junyaku). A CHO-K1 cell line stably expressing bovine LOX-1 (BLOX-1-CHO) was established and maintained in Ham's F-12 medium (Nissui) containing 10% (v/v) heat-inactivated FCS and 10 g/ml blasticidin S as described previously (3) .
Antibodies-A murine anti-bovine LOX-1 monoclonal antibody (29-1) was prepared by immunizing mice with a recombinant protein corresponding to the extracellular domain of bovine LOX-1 as described previously (3) and was used for immunoblotting. A rat anti-bovine LOX-1 monoclonal antibody (5-144) was produced by immunizing rats with BLOX-1-CHO cells. Hybridomas were screened by cell enzymelinked immunosorbent assay (ELISA 35 S]methionine (200 Ci/ ml; NEN Life Science Products) was added and incubated at 37°C for 20 min. Cells were washed with PBS and incubated with DMEM and 10% FCS containing 1 mg/ml methionine for the indicated time periods. After cells were washed with cold PBS and lysed in 500 l of lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.1% (w/v) SDS, 0.5% (w/v) deoxycholate, 0.1% (v/v) Triton X-100, 10 mg/ml leupeptin, and 1 mM phenylmethylsulfonyl fluoride), whole cell lysates were incubated for 30 min at 4°C in a rotator and centrifuged at 13,000 ϫ g for 10 min at 4°C.
Immunoprecipitation of LOX-1-After 40 l of a 50% slurry of protein G-Sepharose (Roche Molecular Biochemicals) was incubated with PBS and 0.1% (w/v) BSA for 2 h at 4°C and with 5 g of rat anti-bovine LOX-1 monoclonal antibody 5-144 for 1 h at 4°C, samples from each time point of a pulse-chase experiment were immunoprecipitated by adding the complexes of anti-LOX-1 antibody and protein G-Sepharose for 2 h at 4°C, followed by centrifugation and extensive washing. After boiling for 5 min in 40 l of Laemmli sample buffer (2% (w/v) SDS, 10% (v/v) glycerol, 60 mM Tris (pH 6.8), and 0.001% (w/v) bromphenol blue) containing 5% (v/v) 2-mercaptoethanol, samples were electrophoresed on 10.5% polyacrylamide gels, followed by autoradiography.
Glycosidase Treatment of LOX-1-LOX-1 absorbed to protein G-Sepharose was treated with several glycosidases essentially as described by Johnston et al. (11) . In brief, the beads were treated with 50 milliunits/ml endo-␤-N-acetylglucosaminidase H (Roche Molecular Biochemicals) for 16 h at 37°C. For treatment with N-glycosidase F (Nglycanase; Takara), the beads were washed and boiled for 5 min in 10 ml of 0.5% (w/v) SDS and 1% (v/v) 2-mercaptoethanol. The volumes were adjusted to final detergent concentrations of 0.1% (w/v) SDS and 1.25% (v/v) Triton X-100 and incubated for 17 h at 37°C in the presence of 50 milliunits/ml N-glycanase. Samples treated with neuraminidase (Seikagaku Kogyo) were incubated with 100 milliunits/ml neuraminidase for 1 h at 37°C. Some samples treated with neuraminidase were then incubated with 100 milliunits/ml endo-␣-N-acetylgalactosamini- Glycosylation Inhibitor-BAECs were cultured in DMEM and 10% FCS containing TNF-␣ (5000 IU/ml) in the presence or absence of 5 g/ml tunicamycin (Wako) for 8 h at 37°C. Cells were lysed in equal amounts of Laemmli sample buffer, and equal amounts of lysates were subjected to immunoblotting. BLOX-1-CHO cells were also cultured in Ham's F-12 medium containing 10% FCS in the presence or absence of 5 g/ml tunicamycin for 12 h at 37°C, and cell lysates were subjected to immunoblotting.
Immunoblotting-Equal amounts of cell lysates were subjected to 10.5% SDS-polyacrylamide gel electrophoresis and electroblotted onto a Protran nitrocellulose transfer membrane (Schleicher & Schü ll). Blotted membranes were probed with murine anti-bovine LOX-1 monoclonal antibody 29-1, incubated with a horseradish peroxidase-conjugated anti-mouse immunoglobulin antibody, and detected by ECL Western blotting detection reagents (Amersham Pharmacia Biotech).
Cell ELISA-After being fixed with 4% paraformaldehyde and PBS for 5 min at 4°C, cells were washed once with PBS and then incubated with PBS and 1% BSA for 30 min at room temperature to block nonspecific binding sites. Cells were incubated with primary antibody 5-144 for 1 h, followed by incubation with a horseradish peroxidaseconjugated anti-rat immunoglobulin antibody for 30 min. Antibody binding was determined using the 3,3Ј,5,5Ј-tetramethylbenzidine substrate system (Dako) by measuring the absorbance at 420 nm. Viable cell numbers were measured by crystal violet staining. In brief, after incubation with 2% (v/v) methanol for 10 min, the cells were stained with 0.5% (w/v) crystal violet (Wako) in 20% (v/v) methanol for 10 min and washed three times with tap water. The stain was eluted from the cells with 0.1 M citrate buffer (pH 4.2) in 50% (v/v) ethanol, and the absorbance at 540 nm was measured. The absorbance at 420 nm from cell ELISA for LOX-1 was corrected by the absorbance at 540 nm from crystal violet staining.
Flow Cytometry-Cells were detached from tissue culture flasks with 1 mM EDTA in PBS and washed with PBS containing 1% (w/v) BSA and 0.1% (w/v) NaN 3 . The detached cells were resuspended in PBS and 1% (w/v) BSA containing anti-LOX-1 monoclonal antibody 5-144 and incubated for 1 h at 4°C. After washing, a fluorescein isothiocyanateconjugated secondary antibody was added, and the cells were incubated for 30 min at 4°C. After washing, cells were analyzed for fluorescence intensity by flow cytometry (FACSvantage, Becton Dickinson). Dead cells were detected by low forward and right angle scatter and excluded from the analysis.
Indirect Immunofluorescence-Indirect immunofluorescence was performed on BAECs grown in four-well chamber slides (Nunc). After being fixed with 4% paraformaldehyde and PBS for 20 min at room temperature, cells were permeabilized with 0.1% (v/v) Triton X-100 and PBS for 1 h and then incubated with PBS, 0.1% (w/v) BSA, and 2% (v/v) normal serum for 20 min at room temperature to block nonspecific binding sites. Cells were incubated with primary antibody 5-144 for 1 h, followed by incubation with a fluorescein isothiocyanate-conjugated secondary antibody for 30 min. After being mounted, cells were visualized using an Axiovert 100 microscope (Carl Zeiss, Inc.) equipped with an LSM 410 laser scanning confocal microscope (Carl Zeiss, Inc.).
Lipoprotein Preparations-Human LDL (1.019 -1.063 g/ml) was isolated from the plasma of healthy human subjects by sequential ultracentrifugation at 4°C. LDL was dialyzed against 3 changes of LDL buffer (150 mM NaCl and 0.24 mM EDTA (pH 7.4)) at 4°C, sterilefiltered, and stored at 4°C. Oxidative modification of LDL was performed by incubation with 7.5 M CuSO 4 at 37°C for 24 h (12). Oxidation of LDL was monitored by the amounts of lipid peroxides by measuring thiobarbiturate acid reactive substances. Values for thiobarbiturate acid reactive substances in Ox-LDL and native LDL were 9.86 and 1.15 nmol of malondialdehyde/mg of protein, respectively. Ox-LDL was radiolabeled with Na 125 I (DuPont) by the iodine monochloride method as described previously (13) .
Binding of 125 I-Labeled Ox-LDL-After being cultured in the presence or absence of 5 g/ml tunicamycin for 12 h, the binding of 125 I-Ox-LDL to BLOX-1-CHO cells was measured as described previously (14) . In brief, adherent cells cultured in 12-well dishes were prechilled in 1 ml of ice-cold DMEM supplemented with 10 mM HEPES-NaOH (pH 7.4) (buffer A) for 30 min at 4°C. Culture media were replaced with 0.5 ml of buffer A containing the indicated amounts of 125 I-Ox-LDL. After incubation for 2 h at 4°C, cells were extensively washed with Tris washing buffer (50 mM Tris-HCl and 150 mM NaCl (pH 7.4)) containing 2 mg/ml BSA, followed by washes with Tris washing buffer without BSA. The cells were dissolved in 0.5 ml of 0.2 N NaOH for 2 h in a shaker, and the radioactivity was measured by a ␥-counter. The mean values for 125 I-Ox-LDL binding in wild-type CHO cells were subtracted from those in BLOX-1-CHO cells to obtain the specific binding activities. The protein concentration of each well was measured by the method of Bradford (41) .
RESULTS

Post-translational Modification of LOX-1-LOX-1 expres-
sion has been shown to be up-regulated by TNF-␣ in BAECs (3). Therefore, BAECs that had been treated with TNF-␣ for 8 h were metabolically pulse-labeled with [
35 S]methionine for 20 min, chased for up to 2 h, and subjected to immunoprecipitation analysis. As shown in Fig. 1A , when BAECs were labeled for 20 min and chased for 0 min, only a precursor form of LOX-1 (pre-LOX-1) with an approximate molecular mass of 40 kDa was visualized. At 20 min of chase, Ͼ50% of the proteins detected were in the 48-kDa mature form. After 40 min of chase, most of the LOX-1 detected was in the mature form. The precursor-mature form relationship of LOX-1 was also examined in BLOX-1-CHO cells by a similar pulse-chase immunoprecipitation analysis. Pre-LOX-1 was detectable within 20 min, and significant levels of the mature form appeared within 40 min (Fig. 1B) . These data indicate that LOX-1 is synthesized as 40-kDa pre-LOX-1 and rapidly modified into the 48-kDa mature form. Glycosidase Digestion of LOX-1-In the amino acid sequence of LOX-1, four potential N-linked glycosylation sites have been identified (3) . Therefore, we sought to determine whether Nlinked glycosylation is responsible for the post-translational processing of pre-LOX-1 into the mature form. BLOX-1-CHO cells were pulse-labeled with [ 35 S]methionine for 20 min and chased for 20 min to obtain equal amounts of labeled pre-LOX-1 and mature LOX-1 as shown in Fig. 1B , and the cell lysates were subjected to various glycosidase digestions. As shown in Fig. 2 , pre-LOX-1, but not mature LOX-1, was sensitive to endo-␤-N-acetylglucosaminidase H, which selectively removes high mannose residues. Treatment with N-glycanase, which cleaves most forms of N-linked carbohydrates, reduced the molecular sizes of both pre-LOX-1 and mature LOX-1 to 32 kDa. Sensitivity to neuraminidase indicated that mature LOX-1 contains certain amounts of sialic acid residues. Additional treatment with O-glycanase after neuraminidase did not affect the molecular mass of LOX-1. LOX-1 expressed in TNF-␣-activated BAECs gave identical patterns of glycosidase digestion (data not shown). These data show that pre-LOX-1 is synthesized by the addition of N-linked high mannose carbohydrates and is further processed into the mature form, which contains certain amounts of sialic acids, without addition of O-linked oligosaccharides.
Effects of Tunicamycin on N-Linked Glycosylation of LOX-1-BAECs
were cultured in the presence of a soluble glycosylation inhibitor, tunicamycin, which completely prevents the addition of N-linked glycans to the nascent polypeptide chain (15) . As shown in Fig. 3A , BAECs treated with tunicamycin exclusively produced a protein with a molecular mass of 32 kDa, which corresponds to LOX-1 lacking all the N-linked glycans. Treatment with tunicamycin also almost completely inhibited the addition of N-linked glycans to LOX-1 in BLOX-1-CHO cells (Fig. 3B) . In addition, the expression levels of these two different forms of LOX-1 were not dramatically different, suggesting that tunicamycin did not significantly affect transcription or translation of LOX-1 in TNF-␣-activated BAECs and BLOX-1-CHO cells (Fig. 3, A and B) .
Roles of N-Linked Carbohydrates in LOX-1 Cell-surface Expression-Cell-surface expression of LOX-1 was measured by cell ELISA and flow cytometry in both tunicamycin-treated BAECs and BLOX-1-CHO cells. In TNF-␣-activated BAECs, cell-surface expression of LOX-1 was diminished after tunicamycin treatment (Fig. 4A) . In contrast, BLOX-1-CHO cells did not show any decrease in LOX-1 cell-surface expression after tunicamycin treatment (Fig. 4B) . Flow cytometric analysis similarly showed that cell-surface expression of LOX-1 in BAECs was reduced after tunicamycin treatment (Fig. 5A) ; however, BLOX-1-CHO cells did not show any significant decreases in LOX-1 cell-surface expression in response to tunicamycin (Fig. 5B) .
Intracellular Localization of LOX-1 Lacking N-Linked Carbohydrates in BAECs-
The intracellular localization of LOX-1 lacking N-linked sugar chains was examined by indirect immunofluorescence confocal microscopy in BAECs. As shown in Fig. 6 , dense immunofluorescence was observed in the cytoplasmic membranes and vesicles, in addition to the perinuclear regions, of TNF-␣-activated BAECs. In contrast, tunicamycin treatment of TNF-␣-activated BAECs abolished the immunofluorescence in the cytoplasmic membranes and vesicles, although the perinuclear staining was preserved. Taken together with the data from cell ELISA and flow cytometry, N-linked carbohydrates on LOX-1 appear to be crucial for its efficient transport to the cell surface in BAECs. (Figs. 4B and 5B) , 125 I-Ox-LDL binding was markedly inhibited over the entire range of Ox-LDL concentrations examined (Fig. 7A) . Scatchard analysis revealed that tunicamycin treatment resulted in a 5-fold decrease in the Ox-LDL binding affinity without a significant effect on the maximal binding capacity (Fig. 7B) . These data thus indicate that N-linked carbohydrate chains of LOX-1 play an important role in the binding affinity for Ox-LDL. DISCUSSION LOX-1 has been identified as a cell-surface receptor for Ox-LDL in vascular endothelial cells (3) . Functional analysis revealed that LOX-1 can support the binding, internalization, and proteolytic degradation of Ox-LDL (3). LOX-1 can also support the binding and phagocytosis of aged red blood cells and apoptotic cells (5) . Recent studies have shown that LOX-1 is expressed in human and murine macrophages in vitro (8, 9) . In human atherosclerotic plaques, LOX-1 is expressed not only by vascular endothelial cells, but also by macrophages and smooth muscle cells (10) . These data imply its physiological roles as a scavenger receptor and its involvement in the pathogenesis of atherosclerosis.
Roles of N-Linked Carbohydrates of LOX-1 in Ox-LDL Binding-LOX-1 is involved in
Bovine LOX-1 consists of 270 amino acid residues with a calculated molecular mass of 30,872 Da. The expressed protein in CHO-K1 cells and BAECs, however, has a molecular mass of 48 kDa (3) . This difference in molecular masses has been speculated to result from the addition of carbohydrate chains at four potential N-linked glycosylation sites in the extracellular C-terminal domain. In this study, we have demonstrated, for the first time, that LOX-1 is synthesized as a 40-kDa precursor protein (pre-LOX-1) containing N-linked high mannose carbohydrate chains, which is subsequently further processed into the 48-kDa mature form. This post-translational modification of LOX-1 occurs more rapidly than those of other membrane glycoproteins such as platelet endothelial cell adhesion molecule-1 and E-selectin (16, 17) . Treatment of both mature LOX-1 and pre-LOX-1 with N-glycanase resulted in reduction of their molecular masses to ϳ32 kDa, which appeared to correspond to the predicted molecular size of LOX-1 lacking all the N-linked carbohydrates. In addition, O-glycanase did not affect the molecular size of LOX-1, thus further supporting that N-linked (but not O-linked) sugar chains are responsible for the cotranslational and post-translational processing of LOX-1.
N-Glycosylation can be found in most membrane proteins; however, the precise functions of N-linked carbohydrates are not fully understood (18) . Several lines of evidence have suggested, however, that glycosylation can be a crucial factor for the folding and trafficking of membrane glycoproteins (19 -22) . N-Linked oligosaccharides can facilitate appropriate protein folding and thus work as a "quality control" system of the endoplasmic reticulum that prevents the transport of inappropriate proteins to the Golgi complex (23) . In the first category, membrane glycoproteins with defects in N-linked glycosylation are retained and ultimately degraded in the endoplasmic reticulum (20 -22, 24) . In the second category, certain glycoproteins are appropriately folded and efficiently transported to the cell surface without N-glycosylation (25) . In the third category, some glycoproteins show decreased levels of cell-surface expression by deglycosylation, possibly because of the alternative mechanisms of protein transport that are independent of the glycosylation state (26) . Since tunicamycin treatment did not completely prevent the transport of LOX-1 to the cell surface in TNF-␣-activated BAECs, LOX-1 appears to fall into the third category. In BLOX-1-CHO cells, however, cell-surface expression of LOX-1 was not affected by the lack of N-linked glycosylation, suggesting that the alternative mechanisms of intracellular transport of LOX-1 may differ among different cell types.
N-Glycosylation of membrane glycoproteins has been shown to be necessary for their ligand binding (25, (27) (28) (29) (30) (31) , signaling (25, (32) (33) (34) (35) , and other biological functions (36 -38) . In BLOX-1-CHO cells, cell-surface expression of LOX-1 was not significantly altered by tunicamycin (Figs. 4B and 5B); however, this glycosylation inhibitor reduced the 125 I-Ox-LDL binding affinity by ϳ80%. This appears to indicate that N-glycosylation of LOX-1 is required for the full ligand binding activity. In contrast, deglycosylated forms of E-selectin, one of the C-type lectin family glycoproteins, were found to be fully active in the adhesion of HT-29 cells (26) , indicating that roles of N-linked carbohydrates in ligand binding may differ among different molecules belonging to the C-type lectin family.
Our previous studies have revealed that the ligand specificity of LOX-1 is distinct from that of other scavenger receptors (4). LOX-1 can bind to Ox-LDL, but not to significant amounts of acetylated LDL. Negative charges on Ox-LDL particles (39) appear to facilitate binding to the positively charged collagenlike domain of class A scavenger receptors (40) . However, interactions between Ox-LDL and LOX-1 may not be simply explained by negative charges on Ox-LDL particles (4). In fact, mature LOX-1 contains certain amounts of negatively charged sialic acid residues (Fig. 2) , but the absence of N-linked oligosaccharides including sialic acids reduces the Ox-LDL binding (Fig. 7) .
In summary, this study demonstrates that LOX-1 is synthesized as a 40-kDa precursor (pre-LOX-1) with N-linked high mannose carbohydrates, which is subsequently further glycosylated and processed into 48-kDa mature LOX-1. N-Linked glycosylation of LOX-1 appears to regulate, at least in part, its intracellular transport and ligand binding. Altered glycosylation of LOX-1 may thus affect its biological functions in vivo and modulate the pathophysiology of diseases including atherosclerosis. Further characterization of the cellular and molecular actions of N-linked carbohydrates on LOX-1 may shed new light on the understanding of the roles of this membrane glycoprotein in the pathogenesis of diseases.
